Company Profile
RenovoRx Stock Price, News & Analysis
- Ticker:
- RNXT
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
1.15 USD (+8.49%)
Close
Last updated: August 6, 2026
41.1M USD
Market cap
Why the stock is moving
Following the latest company update, “RenovoRx Announces First Commercial Clinical Use of RenovoCath® in Sarcoma Patient Treatment, Marking Expansion of Targeted Drug-Delivery Device to Other Solid Tumors”, RNXT closed up 8.49% at $1.15 on Aug 6, 2026. The move occurred in the trading session associated with this commercial update.
Company overview
Targeted Intra-Arterial Drug Delivery
RenovoRx develops a localized drug-delivery approach intended to concentrate chemotherapy within solid tumors while reducing systemic exposure. Its technology combines an FDA-cleared device with an investigational treatment protocol.
RenovoCath
RenovoCath is a dual-balloon infusion catheter designed to isolate a vascular segment and deliver therapy directly through the arterial wall. The device is commercially available to cancer centers as a stand-alone delivery product.
TIGeR-PaC
The Phase 3 TIGeR-PaC trial is evaluating RenovoCath-mediated intra-arterial gemcitabine for locally advanced pancreatic cancer. Overall survival is the principal registrational objective, and successful results could support a future NDA.
Future catalysts
Completion of enrollment in the Phase 3 TIGeR-PaC trial expected by mid-2026.
Final TIGeR-PaC data anticipated in 2027.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of RenovoRx (RNXT)?
RenovoRx (RNXT) most recently closed at 1.15 USD, a +8.49% move versus the previous session.
What is the market cap of RenovoRx (RNXT)?
RenovoRx currently has a market capitalization of 41.1M USD on BioPharmSignal.
What does RenovoRx do?
Targeted Intra-Arterial Drug Delivery RenovoRx develops a localized drug-delivery approach intended to concentrate chemotherapy within solid tumors while reducing systemic exposure. Its technology combines an FDA-cleared device with an investigational treatment protocol. RenovoCath RenovoCath is a dual-balloon infusion catheter designed to isolate a...
On which exchange is RNXT stock listed?
RenovoRx (RNXT) is associated with NASDAQ, United States, Biopharma.
What is Targeted?
Targeted Intra-Arterial Drug Delivery RenovoRx develops a localized drug-delivery approach intended to concentrate chemotherapy within solid tumors while reducing systemic exposure.
Which conditions is RenovoRx targeting with Targeted?
RenovoRx is associated with cancer therapeutics based on its company overview and current catalyst commentary.
How does RenovoRx describe recent progress with Targeted?
Completion of enrollment in the Phase 3 TIGeR-PaC trial expected by mid-2026. Final TIGeR-PaC data anticipated in 2027.
What is Intra-Arterial?
Targeted Intra-Arterial Drug Delivery RenovoRx develops a localized drug-delivery approach intended to concentrate chemotherapy within solid tumors while reducing systemic exposure.